Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease.

This study has been completed.
Information provided by (Responsible Party):
Centocor Ortho Biotech Services, L.L.C. Identifier:
First received: February 26, 2007
Last updated: April 9, 2014
Last verified: April 2014
The purpose of this study is to examine the association with EBV infection, monitor the occurrence of lymphoma and assess lymphoma risk in patients with rheumatoid arthritis and/or Crohns disease and you have taken infliximab.

Condition Intervention Phase
Other: No intervention
Phase 4

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: A Review of Reports of Lymphoma Occurring in Patients With Rheumatoid Arthritis or Crohn's Disease in Centocor-Sponsored and Centocor-Supported Disease Registries

Resource links provided by NLM:

Further study details as provided by Centocor Ortho Biotech Services, L.L.C.:

Primary Outcome Measures:
  • Occurrence of lymphoma [ Time Frame: 5 years ]
    To examine the occurrence of lymphoma among patients in one Centocor-sponsored and Centocor-supported disease registries

Secondary Outcome Measures:
  • Assessment of lymphoma risk [ Time Frame: 5 years ]
    To assess lymphoma risk in relevant registry patient populations, including patients not receiving anti-TNF therapies, patients receiving conventional immunosuppressants (including corticosteroids), and patients receiving anti-TNF therapies

  • Evaluation of association of Epstein-Barr Virus (EBV) with the lymphoma [ Time Frame: 5 years ]
    To evaluate all available data on tissue samples of individual lymphoma cases for the potential association of EBV with the lymphoma.

Enrollment: 120
Study Start Date: February 2006
Study Completion Date: August 2006
Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Patients with lymphoma
Lymphoma Occurring in Patients with Rheumatoid Arthritis or Crohn's Disease
Other: No intervention
All treatments are prescribed by a physician on the basis of usual clinical practice.

Detailed Description:
This is an observational (review of records), retrospective (research activity that is performed after the events under the study have occurred), registry study where data was collected from 3 different registries sponsored or supported by Centocor. Registries are Centocor-sponsored Therapy Resource Evaluation and Assessment Tool (TREAT™) Registry of Crohn's Disease, and in the following two Centocor-supported registries the Consortium of Rheumatology Researchers of North America, Inc. (CORRONA) registry and the Infliximab RA Registry, a subset of the National Database Registry of Rheumatoid Arthritis (NDBRRA) and of the National Databank for Rheumatic Diseases (NDB). A registry is data collection in a real life physician-patient setting. Physicians prescribe medications for rheumatoid arthritis and/or Crohns disease in accordance with their usual clinical practice and then record this information and provide it to Centocor. For this registry study, Centocor collected data from 3 registries to evaluate the risk of getting lymphoma if you have rheumatoid arthritis and/or Crohns disease and you have taken infliximab. Patients who were in one of the 3 registries and had rheumatoid arthritis and/or Crohns disease and did not take infliximab were also evaluated. This registry study does not involve the use of any investigational drugs.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with Crohns disease or rheumatoid arthritis who participate in the specified registries will be included in the analysis. For the lymphoma analysis, patients must be recorded as having a lymphoma during their participation in one of these registries

Exclusion Criteria:

  • Patients who do not have Crohns disease or rheumatoid arthritis and who did not participate in one of the identified registries will be excluded from the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00440817

United States, Illinois
Highland Park, Illinois, United States
United States, Kansas
Wichita, Kansas, United States
United States, New York
Albany, New York, United States
Sponsors and Collaborators
Centocor Ortho Biotech Services, L.L.C.
Study Director: Centocor Ortho Biotech Services, L.L.C. Clinical Trial Centocor Ortho Biotech Services, L.L.C.
  More Information

Additional Information:
Responsible Party: Centocor Ortho Biotech Services, L.L.C. Identifier: NCT00440817     History of Changes
Other Study ID Numbers: CR011239
C0168T68 ( Other Identifier: Centocor, Inc. )
Study First Received: February 26, 2007
Last Updated: April 9, 2014

Keywords provided by Centocor Ortho Biotech Services, L.L.C.:
Rheumatoid arthritis
Crohn's disease

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Crohn Disease
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases processed this record on May 25, 2017